Moreover, at the present time of manuscript, the FDA has approved anti-PD-1/PD-L1 therapy for four histologic types of cancer: melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and metastatic urothelial carcinoma, all of which are epithelial carcinoma [5]. The gene discussed is CD274; the disease is carcinoma.